Single Source Competition for Continuation of Understanding and Targeting the Pathophysiology of Youth-Onset Type 2 Diabetes Clinical Centers (U01 Clinical Trial Not Allowed)

This funding opportunity is issued by the National Institutes of Health, which operates under the U.S. Department of Health and Human Services and serves as the primary federal agency responsible for biomedical and public health research. Within NIH, the National Institute of Diabetes and Digestive and Kidney Diseases oversees research initiatives related to metabolic disorders, including diabetes. This opportunity is structured as a cooperative agreement, indicating substantial federal involvement in the execution and oversight of the funded project. It is presented as a forecasted notice and represents a continuation of an existing research consortium rather than an open, broadly competitive program. The purpose of this funding opportunity is to support the continuation and completion of the DISCOVERY of Risk Factors for Type 2 Diabetes in Youth Study. This initiative is a multi center longitudinal consortium involving numerous clinical sites that collectively investigate the progression and underlying biological mechanisms of youth onset type 2 diabetes. The study focuses on early pubertal youth who are at elevated risk for developing the disease and involves long term follow up to generate a robust dataset. The funding will specifically sustain the infrastructure necessary to complete the scientific objectives already underway. The scope of funding is centered on maintaining and supporting the Biostatistics Research Center, which serves as the coordinating hub for the consortium. This includes responsibilities such as protocol implementation, data management, statistical design and analysis, quality assurance, and coordination across all participating clinical sites. The funding is intended to preserve the integrity of the longitudinal dataset and ensure continuity of operations across the consortium. As a cooperative agreement, the recipient is expected to collaborate closely with NIH program staff, adhering to established protocols and contributing to shared governance structures. Eligibility for this opportunity is highly restricted due to its designation as a single source competition. Rather than being open to a broad pool of applicants, only specific eligible organizations will be invited to apply. This implies that the funding is intended for an existing entity or entities already involved in the DISCOVERY consortium, particularly those with established infrastructure and experience managing the Biostatistics Research Center functions. Applications will still undergo NIH standard peer review processes, and only those deemed meritorious will receive funding consideration. The application process will follow standard NIH submission procedures once the opportunity is formally posted. The estimated posting date is February 2, 2027, with an anticipated application due date of March 10, 2027. Applicants will need to prepare a full proposal consistent with NIH requirements, including detailed research plans, budgets, and supporting documentation. There is no indication of a required pre application such as a letter of intent in the forecast notice. Following submission, applications will be peer reviewed, and funding decisions will be based on scientific merit and alignment with program objectives. The anticipated award date is November 1, 2027, with the project expected to begin on December 1, 2027. The total estimated program funding is thirty five million dollars, with one award expected to be made. There is no cost sharing or matching requirement associated with this opportunity. For additional information or inquiries, applicants are directed to contact the Division of Diabetes, Endocrinology and Metabolic Diseases at the provided NIH email address. As a continuation mechanism, this opportunity is not recurring in the traditional sense but is tied to the lifecycle of an ongoing longitudinal research initiative.